Correction on SR17018 being a PAM, not a partial or full agonist with low efficacy
I tried SR for several months, it never covered my withdrawals enough for me. But I had a very very high tolerance and 18 years of hard opioid and opium use under my belt. I never really used Kratom products. I used diacetylmorphine, morphine, oxycodone, hydrocodone, hydromorphone, oxymorphone (was my favorite, I’d call it the champagne of opiates)
Anyway I recently detoxed at an accelerated outpatient program that uses naltrexone and a large amounts of comfort meds (including Valium, clonidine, gabapentin, etc) to get you through it. I did an 8 day detox off a habit that I had tapered down to 120mg of methadone or about 1g per day worth of intranasal diamorphine at 82% purity.
I wanted to give a brief history, but really the point of my post is this. After studying Dr. Laura Bohn’s research and reading every study available on SR-17018, I frequently see it misquoted as an orthosteric binding low efficacy partial or full agonist.
To briefly go over orthosteric vs allostetic binding:
Orthosteric binds to the primary site of the receptor to put it in an ON state. All current opioids and opiates that exist are Orthosteric binders.
Allostetic means it binds to a different part of the receptor and modulates it positively or negatively. PAM is a positive allostetic modulator. NAM would be be a negative allostetic modulators that reduces the natural binding.
One example of a PAM are benzos. Rather then bind directly to the GABA receptors they bind allostetically and increase the activity on the site with the brains natural receptors
What makes SR17018 different than other opioids is its a PAM. It seems to positively modulate on an allostetic site, allowing the receptors to interact with the brains natural endorphins, however they bind to a much greater extent than without.
However one side note, based on personal experience and some others I’ve read. High dose SR17018 used over several months may block the opiate receptor orthosterically.